How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Endpoints exclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney

calendar_today July 15, 2026 person curtisae3466d673 domain nava-therapeutics

CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – July 15, 2026 – Nava is planning its first clinical trial in autoimmune disease in the first half of 2027.

open_in_new Read original post